Search liu.se

The aim of our research is to identify, validate and implement genetic markers or other biomarkers to predict drug metabolism or drug effects.

The aims of our research are to uncover the cellular and molecular mechanisms that predispose to systemic and long-term anti-tumor immunity and the mechanisms that drive resistance to immunotherapy.

By integrating device engineering with biophysical insights, this project drives the development of smarter drug delivery systems with refined dose adjustments to push the boundaries of precision in preclinical medical sciences.

The Nucleic Acids Technologies Lab explores the use of nucleic acids as biorecognition molecules to develop highly specific and sensitive systems, with various detection modalities.

We reported a novel finding on the highly restricted and biased specificities of CLL Abs some years ago, showing limited target structures for the CLL Abs, which were exposed on oxidized-LDL, apoptotic cells...

Molecular genetic analysis of endocrine tumors (thyroid, parathyroid, adrenal, neuroendocrine): pathogenesis and development of metastases.

Our research aims to understand the function of DNA methylation in the biology of human CD4+ T-cells, and use this knowledge to dissect its role in disease.

WCMM at LiU focuses on the medicine-technology interface, and build upon our existing strengths in research within medical technology, materials science and bioengineering.

Regulation of survival and differentiation of hematopoietic stem cells and leukemia-initiating cells.

Researchers made an unexpected discovery while investigating genetically unique women. Their insights advance our understanding of our most enigmatic chromosome, the X chromosome.